The thesis

Globus Medical is a medical technology company with 27.0% revenue growth and 18.7x P/E ratio. The conviction tier is WATCHLIST with a score of 18/100. Analyst consensus rating is BUY, despite the company not being in the TTG. The setup is interesting due to the high net margin of 1892.0% and gross margin of 6786.0%

Why now

The current macro context, including China's chip tool push and the US-China squeeze, makes GMED's valuation risky. The company's high P/E ratio and low conviction score make it vulnerable to market fluctuations

What to watch

The company's revenue growth and net margin over the next 1-3 quarters will be key indicators of its ability to sustain its current valuation. The DCF intrinsic value of $38 will also be an important metric to watch, as it may indicate a potential mismatch between the company's valuation and its underlying fundamentals

Key risks

Valuation risk is a major concern due to the high P/E ratio. Execution risk is also a factor, as the company's high growth rate may be difficult to sustain. Macro risk, including the US-China trade tensions, could also impact the company's performance